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Introduction
"Shock" is a term used to describe a situa-
tion of cardiovascular collapse. It can arise
from several causes and is usually divided into
several categories, including: cardiogenic,
hemorrhagic, septic, endotoxic, and trau-
matic shock. These categories are broadly
connected by the underlying ultimate failure
of the cardiovascular system.
Shock therapy is an exciting area of ongo-
ing research. Before examining the more re-
cent developments in this area, it is appropri-
ate to review some basic pathophysiology and
current concepts about the treatn1ent of
shock. Veterinary medicine provides several
examples of the various categories of shock.
The hit-by-car dog, the horse with colic, and
the severely dehydrated kitten are familiar to
every practitioner. These cases all present
with compromised cardiovascular function.
Traumatic injury and blood loss, endotoxic
impairment of the myocardium, and loss of
extracellular fluid volume all lead to decreased
perfusion of vital organs. These organs then
begin to fail from lack of nutrition and/or ac-
cumulation of waste products. The failure of
critical organ systems further compromises
cardiovascular function, and thus a vicious
cycle is established.
This phenomenon is fairly well understood,
and the currently accepted treatments for
shock are directed towards maintaining or re-
establishing organ perfusion. These treat-
ments include blood volume replacement and
the administration of vasoactive drugs.
Choices for extracellular volume replace-
ment are currently limited to whole blood,
plasma, crystalloids, and colloids. Each sub-
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stance has its own advantages and disadvan-
tages. Whole blood is required when the oxy-
gen carrying capacity of the blood has been
reduced. It is generally accepted that a PCV
greater than 20 percent is desirable for ade-
quate oxygen transport. However, whole
blood must come from donor animals or from
storage. Donor animals are expensive to
maintain and there is always a chance of in-
compatability problems, although less than in
human medicine. Stored blood may suffer
from depletion of 2,3-diphosphoglycerate, de-
pleted calcium, excess potassium, and the
presence of microaggregates.
Colloids
Colloid volume expanders include plasma
and artificial colloids such as the dextrans and
starch compounds. These substances are used
when the oncotic pressure is reduced as is the
case when the plasma protein is less than 3.5
gm/dl. Two synthetic substances are currently
marketed. They are the dextrans, one of high
molecular weight (dextran 70) and one of low
molecular weight (dextran 40) and hydroxy-
ethyl starch (hespan).l Both of the dextrans
can decrease blood viscosity and decrease pla-
telet aggregation. The lower molecular weight
dextran has a shorter half-life, only 3.5 hours
compared to 72 hours for the dextran 70. The
dextrans cause a shift of body fluid from the
intracellular compartment to the extracellular
compartment as part of their mechanism of
blood volume expansion.
The other alternative to plasma is hydroxy-
ethyl starch. This substance is composed of
polymerized starch molecules. It has been
used in human medicine as volume replace-
ment for cases of hypovolemic shock. It com-
pares favorably with albumin and is much less
expensive. 3
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Blood Substitutes
Recently, there has been some exciting
work with "blood substitutes." These chemical
compounds are designed to carry oxygen to
the tissues as well as replace lost volume. The
ideal blood substitute must be immediately
available, cause no acute or long-term side
effects in the patient, and must not interfere
with subsequent laboratory tests run on the
patient's blood. 2 There are currently two areas
of interest in the artificial blood substitute
field.
Perfluorochemicals are a group of aliphatic
compounds in which all the C-H bonds have
been replaced with C-F bonds. 2 These com-
pounds have a greatly enhanced ability to
carry dissolved gases. One commercially
available perfluorochemical, Fluosol DA, is
currently undergoing clinical trials. Practical
application of perfluorochemicals may be lim-
ited because they require hyperbaric condi-
tions (greater than 75% oxygen) to deliver
sufficient an~ounts of oxygen to the peripheral
tissues, have prolonged retention times in the
patient, and occasionally cause severe hypo-
tension due to an allergic type of response in a
small percentage of patients.
Hemoglobin solutions are another alterna-
tive in the blood substitute field. Hemoglobin
is easily removed from the red blood cell and
retains its oxygen-carrying capacity. Free he-
moglobin is also compatible with aqueous so-
lutions and carries no compatability antigens.
Unfortunately, free hen~oglobin has a short
life of about 3 hours and is reluctant to release
bound oxygen at normal tissue oxygen ten-
sions. 2 Recently, researchers have been able to
improve vascular retention and decrease oxy-
gen affinity by chemical modification of the
hemoglobin molecule. One such modification
is called pyridoxalated stroma-free hemoglo-
bin. This compound compares favorably to
fluosol in its ability to transport oxygen to tis-
sues. 4 It also does not appear to compromise
the reticuloendothelial system's ability to re-
spond to sepsis when used for resuscitation in
rats. 5 Researchers have recently begun to
study bovine hemoglobin solutions because of
their availability and uniform hemoglobin
type. Preparation of the polymerized hemo-
globin is technically difficult, but the end
product is an excellent blood substitute in
hemorrhagic shock treatment. 6
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Glucocorticoids
Glucocorticoids are often administered in
cases of septic shock. It is thought that their
beneficial effects stem from their ability to sta-
bilize cell membranes. Membrane stabiliza-
tion prevents the release of lysosomal enzymes
and reduces subsequent damage by these en-
zymes. These same enzymes are used by the
leukocytes to eliminate invading bacteria.
Treatment of shock with glucocorticoids may
predispose to secondary bacterial infection. 7
Since lysosomal enzymes depend heavily on
the generation of oxygen-free-radicals to pro-
duce their effects, it has been suggested that
free-radical scavengers may be as effective in
preventing cellular damage without increas-
ing subsequent susceptibility to infection. 7
Both ACTH and the beta-endorphins are
released from the anterior pituitary in shock
situations. Administration of massive doses of
steroids may inhibit the release of ACTH
and, coincidentally, the beta-endorphins. 8 A
more recent study has shown that dogs treated
with methylprednisolone, followed by nalox-
one had a dereased survival time when com-
pared to dogs treated with naloxone alone. 9
Prostaglandins
Prostaglandins are endogenously secreted
products of the arachidonic cascade. They
have a variety of actions in the body, depend-
ing on the location. They are vasodilatory in
some vascular beds and cause vasoconstric-
tion in other areas. Therefore it is not surpris-
ing that both administration of specific pros-
taglandins and the administration of pro-
staglandin synthesis blockers have been found
to be beneficial in shock treatn1ent.
Two of the prostaglandins, PGEl and
PG12, have some of the same beneficial effects
as corticosteroids. These include improved
cardiac output and increased membrane sta-
bility. In addition, PGEl may reduce platelet
aggregation and preserve cell energy stores.
One study has shown that PGE1-treated dogs
survived experimental hemorrhagic shock
much longer than those treated with cortico-
steriods. 10
On the other hand, treatment with aspirin
or indomethacin has also improved survival in
several shock models. Both of these non-ste-
roidal anti-inflammatory drugs block pros-
taglandin synthesis or release. They also have
other properties, including inhibiting the re-
lease of 5-hydroxytryptamine from platelets,
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stabilizing lysosomes, inhibiting platelet re-
lease mechanisms, and decreasing vascular
pern1eability.11 It is very possible that the
beneficial effects of non-steroidal anti-inflam-
matory agents are due to one or more of these
activities.
Naloxone
There is currently an ongoing debate con-
cerning the use of naloxone in shock therapy.
This opiate antagonist may act by blocking
the activity of endogenous endorphins. These
endorphins are thought to cause some of the
hypotension associated with shock. 12 Ad-
ministration of naloxone will reverse hypo-
volemic shock in dogs. 13 It also in1proves sur-
vival in endotoxic shock models. 14 There has
been some controversy concerning the exact
mechanism of naloxone used in such situa-
tions, and several authors have suggested that
naloxone effects may be the result of "a mech-
anism unrelated to its opiate antagonism;'15 It
has been shown that administration of both
naloxone and cyproheptadine, an antisero-
tonin drug, is beneficial in traumatic shock.
Both treatments resulted in decreased
pulmonary platelet trapping and decreased
platelet aggregability following traumatic
shock. However, only naloxone will prevent
the hypotension associated with traumatic
shock. 16 The anti-shock dosages of naloxone
used in many of studies are very large, rang-
ing from 0.5 to 5 mg/kg.
Antihistamines
Other unlikely agents that could possibly be
useful in the treatment of shock are the H 1
antihistamines. Administration of prometha-
zine, an H 1 antagonist, increases the survival
time of dogs subjected to experimental hemor-
rhagic shock. 17 Histamine release in shock sit-
uations is thought to depress cardiovascular
function. Promethazine also exhibits some al-
pha-adrenergic activity which may alter re-
sponses to hemorrhagic shock.
Dichloroacetate
Dichloroacetate is an interesting chemical
that has the ability to increase the ac~ivity of
pyruvate dehydrogenase. This increased ac-
tivity leads to more rapid oxidation of
pyruvate to acetyl-CoA. This prevents the
conversion of pyruvate to lactic acid and pro-
motes the oxidation of lactic acid to pyruvate.
Dichloroacetate will prevent the buildup of
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lactic acid and reverse existing lactic acidemia
in endotoxic shock models and also in phen-
formin-induced lactic acidosis in the dog. 18.19
Dichloroacetate has also been used success-
fully to reduce the lactic acid levels of humans
with lactic acidemia of various etiologies. 20
Aprotinin
Aprotinin is a basic polypeptide that is a
potent protease inhibitor and inactivator of
the Kallikrein-kinin system. It is marketed
under the trade name of Trasylol. Kallikrein-
kinin system activation results in increased
vascular permeability, which may lead to
pulmonary insufficiency. Treatment with
aprotinin has been shown to reduce the inci-
dence and severity of puln10nary insufficiency
after traumatic injury in humans. 21 It has also
been postulated that aprotinin acts by reduc-
ing the activity of lysosomal enzymes released
into the cell during shock. This would result
in a more rapid regeneration of intracellular
ATP and allow the cell to recover more rap-
idly from hypoxia. 22
Calcium Channel Blockers
The calcium channel blockers include vera-
pamil, nifedipine, and diltiazem. These drugs
act to inhibit the influx of calcium into the cell
through the "slow channels." They are most
recognized for their beneficial effect on the
cardiovascular system. They act to depress
cardiac contractility and heart rate and pro-
tect the myocardium from ischemic damage.
They are also powerful vasodilators. 23 It has
also been reported that treatment with vera-
pamil will prevent small bowel hemorrhage
during hemorrhagic shock in the dog. Cal-
cium-dependent portal hypertension may be
the underlying mechanism of small bowel
hemorrhage. 24 More recently, it has been pos-
tulated that hypoxia will trigger massive cal-
cium influx into vascular endothelium result-
ing in arteriolar spasm. This spasm is then
responsible for the decreased perfusion of or-
gans seen after anoxia. A great deal of interest
has been elicited by the implications of treat-
ment for cerebral anoxia. Studies have shown
that verapamil and other calcium antagonists
will protect cerebral cortical blood flow and
oxygen consumption after cardiac arrest in
dogs. 25
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Substrate Replacement
There has recently been a great deal of in-
terest in the actual events at the cellular level
during shock. Studies have shown that hypo-
xia causes a cellular "energy crisis" by deple-
tion of mitochondrial and intracellular ATP.
This results in failure of transport mecha-
nisms and alterations of cellular mem-
branes. 26 This introduces another possible
avenue of shock therapy, administration of
energy substrates. Possible candidates include
glucose, cyclic AMP, Krebs cycle intermedi-
ates, adenosine and inosine, creatinine phos-
phate, and finally, adenosine triphosphate. 27
Direct administration of ATP is perhaps the
most appealing because it is the basic unit of
energy in the cellular economy. Treatment
with ATF-MgCb complex is beneficial in a va-
riety of shock models. 27 ATP-MgCb adminis-
tration following shock and ischemia will im-
prove metabolic capacity by restoring
intracellular ATP levels. This leads to im-
proved cellular function. ATP-MgCb may im-
prove blood flow, improve microcirculation,
induce more rapid recycling of energy capa-
bility, and restore normal membrane func-
tion. 26 These effects are not yet fully docu-
mented.
DMSO
DMSO is representative of a class of com-
pounds called the free-radical scavengers.
Free-radicals have received some attention as
possible mediators of cellular damage follow-
ing ischemia. One source of these free-radi-
cals is the enzyme xanthine oxidase. A recent
study has shown that treatments with allo-
purinol, an inhibitor of xanthine oxidase, or
DMSO were both effective in preventing vas-
cular injury following ischemia. 28
Captopril
Captopril is an inhibitor of angiotensin II
formation. Since angiotensin II is a potent va-
soconstrictor, it has been postulated that ad-
ministration of captopril may be beneficial in
shock. Studies have shown that treatment
with captopril will protect cardiovascular and
metabolic parameters during endotoxic shock
in the miniature pig. 29
Carboxylic Ionophores
The carboxylic ionophores include such
chemicals as monensin, lasalocid, and salino-
mycin. These compounds act by increasing
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intracellular calcium content and have been
shown to increase coronary blood flow,
myocardial contractility, cardiac output, and
blood pressure. Monensin-treated dogs sub-
jected to endotoxic shock showed dose-de-
pendent increases in these parameters.
Monensin appears to have a selective cor-
onary vasodilatory action. Some of the phar-
macological effects of n10nensin may be due to
other mechanisms such as release of endoge-
nous catecholamines. 30
Summary
It is apparent that there has been a great
deal of research and progress in the field of
shock therapy. Although most of the interest
has been in applying these advances to human
medicine, it is inevitable that many of these
ideas will become integrated into veterinary
medicine. It is perhaps ironic to note that
many of these advances were initially refined
using animal models. In any case, there will
most likely be further advances in this area as
we learn more about shock and its many in-
teractions and consequences in the body.
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